Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KAT2A (GCN5) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KAT2A HAT / Bromodomain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View KAT2A Products |
| Gene Delivery | KAT2A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View KAT2A Products |
| Benchmark Ab | Anti-KAT2A Benchmark Antibody Recombinant positive control for western blot and target detection. |
View KAT2A Products |
| Validator | KAT2A siRNA Set For knockdown verification and synthetic lethality assays. |
View KAT2A Products |
| Related Target A | KAT2B (PCAF) Primary homolog for selectivity counter-screening. |
View KAT2B Products |
| Related Target B | EP300 Recombinant Protein Related HAT for broad counter-screening. |
View EP300 Products |
| Related Target C | MYC Downstream oncogene for transcriptional readout validation. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (KAT2B/PCAF) | Human KAT2A & KAT2B proteins with >95% purity, verified by mass spec and sequence analysis. |
| Broad HAT Family Counter-screening | Homolog panel (KAT2A, KAT2B, EP300) for off-target profiling. |
| Domain-specific targeting (Bromodomain vs HAT) | Rationally designed, specific truncated domain recombinant proteins with Theoretical MW precision. |
| Cellular Target Engagement | KAT2A ORF Lentivirus for stable cell line construction; validated siRNA for genetic validation. |
| Lack of Controls | Recombinant Benchmark Antibodies included for precise detection. |
| False Positives in Cellular Assays | Sequence-verified siRNA and high-specificity antibody for orthogonal confirmation. |
Live KAT2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KAT2A (GCN5) therapeutics is intensifying as the field of epigenetics matures, with major players focusing heavily on Small Molecule Inhibitors and emerging PROTACs. As an essential histone acetyltransferase and critical component of the SAGA complex, KAT2A drives oncogenic transcriptional programs, particularly in Acute Myeloid Leukemia (AML) and various solid tumors. As first-generation therapies advance through preclinical validation, the next wave of R&D is targeting dual KAT2A/B inhibitors to prevent compensatory upregulation, allosteric modulation, and targeted protein degraders to completely ablate the scaffolding functions of the protein complex. This multi-pronged approach aims to achieve differentiated pharmacology in both hematologic malignancies and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Mol (HAT Inhibitors) | Emerging Biotechs, Academic Spin-offs | AML, Lymphoma | Enzymatic Assay Controls (Need high-purity HAT domains) |
| Small Mol (Bromodomain) | Epigenetic-focused Pharma | Solid Tumors (Lung, Breast) | Binding Affinity Screening (Need precisely truncated Bromodomains) |
| Allosteric Inhibitor | Early discovery consortia | Oncology | Binding Kinetics (Need full-length recombinant KAT2A for SPR/BLI) |
| PROTAC / Degrader | Preclinical Innovators | Refractory Cancers | Ternary Complex Validation (Need native-folded WT proteins) |
| siRNA / Gene Therapy | Preclinical Discovery | Metabolic Disorders | Knockdown Validation (Need Sequence-verified siRNA sets) |